Skip to main content

Table 4 Change in estimated 10-year CVD risk and key measures at study closeout

From: A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization

 

Standard Practice

(N = 104)

Polypill

(N = 99)

  
 

Baseline

Exit

Diff

Baseline

Exit

Diff

Diff of Differences

(95% CI)

P-value

Estimated 10-year CVD risk (%)

41.6 ± 19.8

11.1 ± 10.0

-30.6 ± 22.8

44.1 ± 20.3

11.5 ± 13.0

-32.7 ± 26.0

2.1 (-4.9, 9.1)

0.56

Systolic blood pressure (mmHg)*

165.0 ± 17.6

138.1 ± 19.3

-26.9 ± 25.7

165.6 ± 19.2

136.8 ± 20.8

-28.8 ± 24.9

1.9 (-5.1, 8.9)

0.60

Total cholesterol (mmol/L)

5.7 ± 1.3

4.7 ± 1.1

-1.0 ± 1.6

6.1 ± 1.3

4.8 ± 1.0

-1.4 ± 1.2

0.4 (0.0, 0.8)

0.07

Creatinine (mmol/L)

90.5 ± 21.2

92.8 ± 24.6

1.3 ± 19.3

87.8 ± 22.6

92.9 ± 25.9

4.8 ± 31.7

-3.5 (-10.8, 3.8)

0.36

Serum potassium (mmol/L)

4.6 ± 0.6

4.5 ± 0.4

-0.0 ± 0.5

4.5 ± 0.5

4.6 ± 0.5

0.1 ± 0.6

-0.1 (-0.3, 0.1)

0.10

Alanine aminotransferase (U/L)

31.9 ± 18.2

36.3 ± 31.6

4.1 ± 25.7

29.8 ± 15.0

33.0 ± 26.0

3.0 ± 17.8

1.1(-5.1, 7.3)

0.72

  1. * Second measured blood pressure